Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...